TORONTO, Oct. 14, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that, under its Co-operative Psychedelics Evaluation…

Source

Previous articleNuminus Upgrades Psychedelics Lab to Increase Research Service Capabilities
Next articleLevitee Labs Appoints Dr. Mohammed Mosli as Chief People Officer of Levitee Clinics and Pharmacies in Alberta, Canada